Indivior Pharmaceuticals Inc (INDV) — ESG & Values Scores

Environment story

Indivior has not disclosed Scope 1, 2, or 3 greenhouse gas emissions, renewable energy percentages, or net-zero targets in the provided 10-K filing. No environmental controversies, toxic waste incidents, water pollution, or habitat protection issues were identified in the source documents. The company manufactures buprenorphine-based pharmaceuticals with no apparent direct carbon-intensive operations beyond standard pharmaceutical manufacturing. Absence of disclosed emissions data results in automatic deductions per rubric; no greenwashing detected as company makes no ESG claims.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Manufacturing Facility Operations

Company operates Fine Chemical Plant in Hull, UK for API production and Raleigh Manufacturing Facility for SUBLOCADE production. Contracts third-party manufacturers (Curia, Aquestive, RB) for finished products. No disclosed sustainability measures or decarbonization investments.

Social story

Indivior resolved a major 2020 DOJ settlement involving false statements related to SUBOXONE Film marketing practices (2012 misconduct), with a wholly-owned subsidiary pleading guilty and $600 million in payments; compliance obligations completed November 2025. No current documented labor union suppression, strikes, or major disputes within 24 months identified. CEO-to-worker pay ratio, workforce turnover rate, and detailed diversity metrics are not disclosed in the 10-K. Leadership diversity data unavailable. The company operates in addiction medicine treating opioid use disorder, demonstrating social mission alignment. Patient access programs including $0 co-pay assistance and criminal justice reentry support noted. No human rights or supply-chain labor violations reported.

Criticisms on file

2020 DOJ Settlement: Subsidiary pleaded guilty to false statements regarding SUBOXONE Film marketing (2012 misconduct); $600 million settlement with federal and state authorities; subsidiary excluded from government healthcare programs; resolution included Corporate Integrity Agreement with HHS-OIG (completed July 2025) and FTC stipulated injunction (expires November 2030).
Source: INDV 10-K Item 1 Business—Agreements with DOJ, FTC and HHS-OIG; federal criminal grand jury investigation began 2013, indictment 2019.

Disclosed initiatives

INSUPPORT Community Reentry Program

Provides up to two months of free SUBLOCADE to eligible patients released from criminal justice system experiencing insurance gaps during reinstatement period.

Expands access to treatment for underserved OUD populations in criminal justice settings.
SUBLOCADE Co-Pay Assistance Program

Over 95% of enrolled patients pay $0 out of pocket through commercial co-pay program. 88% of insured lives have payor coverage.

Removes financial barriers to medication access.
Corporate Compliance Program

Chief Integrity and Compliance Officer reports to CEO; Compliance Committee provides Board oversight; external consultants assess effectiveness; robust 'Speak-Up' mechanism with anonymous reporting; team includes professionals with 50+ years combined healthcare compliance experience.

Post-settlement governance strengthening and culture remediation.

Governance story

Indivior Pharmaceuticals Inc completed U.S. domestication on January 23, 2026, changing from UK PLC to Delaware corporation. No dual-class share structure disclosed post-domestication. Board independence percentage not provided in 10-K. CEO Joseph Ciaffoni appointed February 2026 and serves on Board; Mark Crossley was predecessor. No active antitrust proceedings identified beyond resolved DOJ/FTC settlement (2020). No climate deregulation lobbying or litigation to block shareholder climate proposals detected. Lobbying expenditure amounts not disclosed. FTC Order compliance obligations extend through November 2030. Recent executive transitions and R&D restructuring (August 2025) and rest-of-world optimization (October 2025) indicate active governance restructuring.

Criticisms on file

2020 DOJ/FTC Settlement Legacy: Wholly-owned subsidiary pleaded guilty to false statements regarding SUBOXONE Film marketing; excluded from government healthcare programs; Corporate Integrity Agreement with HHS-OIG (completed July 2025); FTC stipulated injunction remains active through November 2030; Resolution Agreement obligations satisfied November 2025.
Source: INDV 10-K Item 1 Business—Agreements with DOJ, FTC and HHS-OIG Regarding Marketing and Promotional Practices.

Disclosed initiatives

U.S. Domestication

Changed domicile from UK to Delaware effective January 23, 2026 via court-approved scheme of arrangement; successor to Indivior PLC; shares included in Russell 2000, Russell 3000 (June 2025) and S&P SmallCap 600 (December 2025) indices.

Alignment with U.S. regulatory and listing standards; improved market accessibility.
Executive Leadership Transition

Joseph Ciaffoni appointed CEO February 27, 2025; Patrick Barry hired as Chief Commercial Officer (May 2025); Vanessa Procter hired as EVP Corporate Affairs (July 2025).

Leadership renewal with new commercial and governance focus.
R&D and Medical Affairs Restructuring

August 2025 announced restructuring of R&D and Medical Affairs organizations including closure of three related locations.

Operational efficiency and strategic realignment.
Rest of World Optimization

October 2025 announced cessation of operations in UK, Ireland, Sweden, Israel, Finland, Italy; maintains operations in Canada, Australia, France; continues manufacturing at Hull FCP; retains employees supporting U.S. and remaining markets.

Geographic focus concentration and cost optimization.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Indivior Pharmaceuticals Inc. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Indivior Pharmaceuticals Inc in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)